
Non-alcoholic fatty liver disease (NAFLD) is marked by liver fat accumulation, progressing to inflammation, fibrosis, and cirrhosis. While drug focus is on advanced stages, studies suggest liver fat quantity is a key independent risk and progression factor for NAFLD and metabolic diseases. The review covers liver fat quantification tools, clinical evidence linking it to NAFLD progression and cardiometabolic issues, and current pharmacological/non-pharmacological fat reduction approaches.
Like
Save
Share